Contact Us

News

Jan 27, 2025

Antharis Therapeutics Elected Monoclonal Antibodies Development Company of the Year 2025

Jan 22, 2025

Antharis Therapeutics’ Dr. Raphael Ribeiro-Pinaud Named Most Iconic Business Leader of 2025

Nov 18, 2024

Antharis Therapeutics Appoints Patric Nelson as Chief Business Officer

Nov 7, 2024

Antharis Therapeutics CEO, Dr. Raphael Ribeiro-Pinaud, Featured in Biotech Leader Spotlight Series

Oct 15, 2024

Antharis Therapeutics Welcomes Daniel Yazbeck as Head of Corporate Strategy

Mar 18, 2024

Antharis Therapeutics CEO Dr. Raphael Ribeiro-Pinaud Named Among “Most Impactful CEOs of the Year 2024" by CIO Today

Feb 19, 2024

Antharis Therapeutics Awarded “Biopharmaceutical Company of the Year 2024 - California” by Global Health and Pharma

Feb 10, 2024

Antharis Therapeutics Recognized as a Leading Emerging Biopharmaceutical Company

Jan 15, 2024

Antharis Therapeutics CEO, Dr. Raphael Ribeiro-Pinaud, Named “Most Inpiring Business Leader of 2024” by CXO Outlook for Pioneering Advances in Biopharma Innovation

Dec 18, 2023

Antharis Therapeutics Selected as a Top 10 Biotech Startup in 2023 by Pharma Tech Outlook for Pioneering Immuno-Oncological Cancer Treatments

Aug 23, 2023

Antharis Therapeutics Acquires Galileo Biotech, including Its GMP-Certified Development and Manufacturing Facility

Jul 14, 2022

Antharis Therapeutics Acquires Cassyni Biopharma and Its Portfolio of Assets

Jul 14, 2022

Antharis Therapeutics Announces Successful Completion of Its Series A Financing Round

760-481-7609
1396 Poinsettia Ave, Vista, CA 92081, United States
Linkedin
contact@antharistherapeutics.com

PRIVACY POLICY & TERMS OF USE

Copyright © 2024 Antharis Therapeutics develops cutting-edge therapies that harness the immune system towards cures for a number of unmet medical needs, including a variety of cancers.